AI Strategy & Implementation for Life sciences
Navigate AI with
A structured, production-grade AI programme for biotech, pharma, CRO, and life science organisations — built to move beyond pilots and into real, regulated impact.
20+
Years in Life
Sciences Tech
ÂŁ50
Blended
Hourly Rate
4
Structured
Engagement Tiers
$150B
AI Pharma Market
by 2034
95%
of enterpirse generative AI pilots deliver no measurable business impact
— MIT NANDA Study, 2025
68%
of pharma & biotech leaders cite poor data quality as the primary cause of AI failure
— Industry Survey, 2025
$8.5B
AI pharma market today, growing to $150B by 2034 — the window to lead is now
— Global Market Intelligence
The Problem
Most AI programmes fail
before they reach production.
Generic consultants build roadmaps. Very few understand how to build AI systems that can survive a GxP audit, integrate with clinical data pipelines, and scale across a regulated organisation.
Fragmented initiatives
Disconnected pilots — trained on synthetic data, siloed from real workflows — rarely create enterprise value. Without orchestration, AI remains an experiment.
Weak data foundations
Poor data quality and governance are the leading causes of AI programme failure in life sciences. Building on unstable foundations guarantees rework.
Increasing regulatory risk
FDA, EMA, and ICH frameworks are tightening around AI validation. Ungoverned use of tools like Copilot or ChatGPT in GxP-adjacent workflows creates real audit exposure.
Generalist advisors, specialist gaps
Most advisors deliver a roadmap. Very few can build AI around molecular pipelines, clinical models, and regulatory processes in a way that passes audit and scales to production.
The Programme
Four pillars. One coherent AI strategy.
Polaris is structured across four integrated engagement layers, each delivering specific, measurable outcomes for the people accountable at that level.
C-Suite & Strategic Leadership
An 18-month AI strategic roadmap co-created with your leadership. Covers investment sequencing, competitive intelligence, board communication architecture, and regulatory engagement strategy. AI strategy that earns board confidence and drives investment decisions.
Operational Execution & Programme Management
AI embedded into how your organisation operates, reports, decides, and manages data. Predictive milestone forecasting, AI-assisted resource allocation, CRO/partner performance AI, and AI-ready data governance built into the operational fabric.
Privacy, Data Sovereignty & Compliance
AI your legal, compliance, and ethics teams can stand behind. Privacy-by-design architecture, differential privacy for genomic and biomarker data, federated learning across sites, and data residency for EU, China, India, and US jurisdictions.
Technical
Architecture & Execution
Production-grade AI built for regulated life-science environments. Foundation model selection across GPT-4o, Claude, Llama, BioGPT, and ChemBERTa. OMOP CDM, FHIR R4, 21 CFR Part 11 compliant hosting. Zero-trust network architecture throughout.
Built on
- GPT-4o
- Claude 3.5 Sonnet
- Llama 3.1
- BioGPT
- ChemBERTa
- AlphaFold 2/3
- PyTorch
- MLflow
- AWS SageMaker
- RDKit
- DeepChem
- OMOP CDM
- FHIR R4
- Medidata Rave
Engagement Packages
Start small.
Scale with confidence.
All hourly work priced at ÂŁ50/hr blended rate. Fixed bundles are complete on their own and feed cleanly into the next tier.
Ignite
8 weeks - ~160 hours
ÂŁ8,000
Fixed scope
For leadership teams needing a credible AI roadmap and one quick-win use case delivered and validated.
~160 hours of expert time
Accelerate
12 weeks · ~320 hrs
ÂŁ16,000
Fixed scope
For organisations ready to deploy 2–3 validated AI systems with governance foundations in place.
~320 hours of expert time
Scale
6 months · custom
Talk to us
Bespoke scope & terms
Enterprise-wide rollout, GxP validation packages, multi-site deployment across your organisation.
Scoped in Week 1
Transform
12 months · embedded
Partnership
Partnership
Full AI Centre of Excellence build-out with an embedded Polaris team and strategic long-term partnership.
Long-term partnership
- 50% commencement fee on signing
- CDA signed before any scientific discussion
- No sub-contracting, no generalist staff rotation
How it works
From discovery to
production in weeks.
All hourly work priced at ÂŁ50/hr blended rate. Fixed bundles are complete on their own and feed cleanly into the next tier.
Discovery Call
A focused 60-minute conversation with our Polaris team. No pitch decks. We map your current AI state, data maturity, and the two or three outcomes that matter most to your leadership team.
Scoped Proposal
Within five working days, you receive a precise scope document. Package, timeline, resource allocation, and measurable outcomes — all defined before a contract is signed.
Engagement & Delivery
Your Polaris team begins work. Weekly exception-based reporting keeps your leadership informed without creating noise. Every deliverable is built for your environment, not a template.
Why o2h Technology
Two decades at the intersection of science and technology.
Polaris is structured across four integrated engagement layers, each delivering specific, measurable outcomes for the people accountable at that level.
- 21 CFR Part 11 compliant infrastructure
- GxP validation-ready AI systems
- CDA signed before any scientific discussion
- Zero-trust network architecture
- FDA, EMA, and ICH aligned governance
- IP assigned to client on full payment
- No sub-contracting, ever
"Many advisors can create a roadmap. Very few understand how to build AI systems around scientific data pipelines, clinical models, and regulatory processes in a way that can scale, survive production, and pass audit."
Polaris Programme, o2h Technology
Polaris Leadership team
Sunil Shah
CEO - o2h Ventures and
Co-Founder - o2h group
Sunil Shah
CEO - o2h Ventures and
Co-Founder - o2h group
A serial entrepreneur having begun a career in the Life Sciences team at PA Consulting group followed by co-founding two companies in the information technology and life sciences sector. The second of these companies, Oxygen Healthcare Ltd was acquired by Piramal Enterprises Ltd (BSE: PEL). Sunil co-founded o2h ventures which involves discovery services / collaborations, seeding drug discovery, academic in-licensing and biotechnology incubation. Sunil has a degree in Biochemistry and an MBA from Cambridge University
Prashant Shah
CEO - o2h technology and
Co-Founder - o2h group
Prashant Shah
CEO - o2h technology and
Co-Founder - o2h group
A serial entrepreneur having begun a career with the Strategy group of at Accenture followed by co-founding two companies in the technology and life sciences sector. The second of these companies focused on drug discovery was acquired by a public company. Prashant co-founded o2h Ventures which is involved in seeding, incubating and investing in early stage life science and technology companies. Prashant has a BEng, MSc and an MPhil in Management.
claudio dastone
claudio dastone
Andy Morly